Summary
Bristol-Myers Squibb Company (BMY) reported total revenues of $4.069 billion for the third quarter of 2015, a 4% increase year-over-year, and $12.273 billion for the nine-month period, up 6%. This growth was driven primarily by strong performance from newer products like Eliquis and the Hepatitis C franchise, along with the continued ramp-up of Opdivo. Net earnings for the quarter were $706 million ($0.42 per diluted share), slightly down from $721 million ($0.43 per diluted share) in the prior year. For the nine months, net earnings were $1.762 billion ($1.05 per diluted share), a decrease from $1.991 billion ($1.19 per diluted share) in the same period of 2014. The decrease in earnings was largely due to increased research and development expenses, particularly related to acquisitions like Flexus Biosciences and upfront payments for new collaborations, partially offset by higher revenues. The company also highlighted a significant increase in cash flow from operations, though it was lower than the previous year due to timing differences in payments and collections. BMY is actively managing its product portfolio, with significant product launches and pipeline advancements, particularly in oncology with Opdivo and immuno-oncology. The company also continues to engage in strategic business development, including acquisitions and licensing agreements, to bolster its future growth prospects. Despite some ongoing litigation and regulatory matters, the company maintains a solid financial position and liquidity.
Financial Highlights
57 data points| Revenue | $4.07B |
| Cost of Revenue | $1.10B |
| Gross Profit | $2.97B |
| R&D Expenses | $1.13B |
| SG&A Expenses | $1.18B |
| Operating Expenses | $3.08B |
| Interest Expense | $41.00M |
| Net Income | $706.00M |
| EPS (Basic) | $0.42 |
| EPS (Diluted) | $0.42 |
| Shares Outstanding (Basic) | 1.67B |
| Shares Outstanding (Diluted) | 1.68B |
Key Highlights
- 1Total revenues increased by 4% to $4.069 billion in Q3 2015 and by 6% to $12.273 billion for the nine months ended September 30, 2015, driven by new product launches and growth in key therapeutic areas.
- 2Net earnings for the nine months decreased to $1.762 billion from $1.991 billion in the prior year, primarily due to higher R&D expenses related to acquisitions and collaborations.
- 3Opdivo, a key immuno-oncology drug, received multiple regulatory approvals and positive clinical data updates during the period for various cancer indications.
- 4Eliquis, an anticoagulant, demonstrated strong revenue growth, contributing significantly to the company's top-line performance.
- 5The company experienced a substantial increase in R&D expenses, including an $800 million acquisition of Flexus Biosciences and upfront payments for new alliance agreements, impacting short-term profitability.
- 6Cash flow from operating activities was $1.221 billion for the nine months ended September 30, 2015, a decrease from $2.576 billion in the prior year, mainly due to timing differences in payments and collections.
- 7BMY completed several strategic business development transactions, including acquisitions and licensing agreements, to strengthen its pipeline and therapeutic focus, particularly in oncology and immunology.